ArticleExperimental and therapeutic medicine2015
Macrolide therapy in cryptogenic organizing pneumonia: A case report and literature review.
Article in Experimental and therapeutic medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 37 citations in OpenAlex.
- Unusual Presentation of Cryptogenic Organising Pneumonia as a Focal Lung Mass: A Case Report and Literature Review.Respirology case reports · 2025Article
- The concurrence of lung malignancies and organizing pneumonia.Frontiers in oncology · 2025Article
- How I diagnose and treat organizing pneumonia in hematopoietic cell transplant recipients.Blood · 2024Review
- Update on cryptogenic organizing pneumonia.Frontiers in medicine · 2023Review
- Extracorporeal Membrane Oxygenation Supported Transbronchial Cryobiopsy in the Diagnosis of Severe Organizing Pneumonia: A Case Report.Frontiers in medicine · 2022Article
- Cryptogenic organising pneumonia: current understanding of an enigmatic lung disease.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 4. Cryptogenic Organizing Pneumonia.Tuberculosis and respiratory diseases · 2021Article
- Pulmonary Toxicities of Immunotherapy.Advances in experimental medicine and biology · 2021Article
- SARS-CoV-2 organising pneumonia: 'Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?'BMJ open respiratory research · 2020Review
- Immune-Related Adverse Events: Pneumonitis.Advances in experimental medicine and biology · 2020Review
- Acute fibrinous organising pneumonia presenting as a cavitary lung lesion and treatment response to azithromycin.BMJ case reports · 2019Article
- Cryptogenic organizing pneumonia masquerading as lung carcinoma: A case report and review of the literature.Experimental and therapeutic medicine · 2018Article
- A 12-week combination of clarithromycin and prednisone compared to a 24-week prednisone alone treatment in cryptogenic and radiation-induced organizing pneumonia.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2018Article
- Long-term macrolides in diffuse interstitial lung diseases.European respiratory review : an official journal of the European Respiratory Society · 2017Review
- Cryptogenic organizing pneumonia-Results of treatment with clarithromycin versus corticosteroids-Observational study.PloS one · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryptogenic organizing pneumonia (COP) is a pulmonary disorder associated with nonspecific clinical presentations. The macrolide class of antimicrobial agents is widely used to treat infectious and inflammatory respiratory diseases in humans. The present study reports a case of COP that was effectively treated with azithromycin in combination with glucocorticoid. A literature review of similar cases is also presented. It was found that all COP patients in the literature received macrolide treatment, including six cases with unknown clinical outcomes. For the remaining 29 patients, 20 patients initially received the macrolide as a single therapy and 4/5 of them (16 cases) were cured with a treatment time of 3-14 months, while 1/5 (4 cases) showed no improvement after treatment for 1 month and were switched to a glucocorticoid or combination treatment with a glucocorticoid, after which the disease was finally well-controlled. Side-effects of macrolide were rare. Based on this analysis, it is recommended that macrolides can be used as a first-line therapy in patients with mild COP. For patients with recurrent COP, it is suggested that macrolides should be used as an adjunctive therapy with other treatments, such as a glucocorticoid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.